News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Sygnature Chemical Services and Heptares Announce Contract Chemistry Collaboration
10/8/2009 1:32:09 PM
Nottingham, UK and Welwyn Garden City, UK – 8th October 2009 – Sygnature Chemical Services Ltd., a leading provider of premium medicinal chemistry and computational chemistry services to the global pharmaceutical industry, and Heptares Therapeutics Ltd., a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), today announced that they have entered into a contract chemistry collaboration in drug discovery. Under the terms of the agreement, scientists from the two companies are working together to advance one of Heptares’ internal high-value GPCR programmes. Sygnature is providing synthetic chemistry services to produce a novel chemical library for Heptares to evaluate against purified, stabilised and functional proprietary GPCR targets (known as StaRs™, Stabilised Receptors).
Commenting on the agreement, Dr Simon Hirst, Sygnature’s Chief Executive Officer, said, “We are delighted that Heptares has chosen to collaborate with Sygnature on this programme. Heptares’ decision to work with us demonstrates our growing reputation for delivering ‘top tier’ science coupled with high value and quality. Over the past five years, Sygnature has established an excellent track record of success and enjoyed healthy growth because of its ability to deliver flexible scientific resource and drug discovery expertise, without high overhead costs. We look forward to building a long-term scientific and business relationship with Heptares.”
Dr Miles Congreve, Head of Chemistry at Heptares said, "We are working with Sygnature on this drug discovery programme which forms a component of our efforts to develop novel GPCR-focused therapeutics. Sygnature is becoming well-known and respected within the pharmaceutical industry for its high-quality medicinal and synthetic chemistry driven services. Sygnature was therefore our choice as a trusted partner to leverage our own internal drug discovery capabilities.”
About Sygnature Chemical Services Ltd.
Sygnature CSL, founded in 2004, is a leading UK-based provider of premium medicinal chemistry, synthetic chemistry, array/focused library and computational chemistry services. The Company delivers high value and quality to its clients by applying in-house scientific expertise and ‘state-of-the-art’ technologies to the discovery of novel drug candidates. Sygnature’s team of 34 industry-experienced chemists (75% with PhDs) undertakes key elements of the drug discovery process, such as hit identification, hit-to-lead and lead optimisation, to afford novel compounds in a time-efficient and cost-effective manner. We work closely with our clients’ scientists to accelerate their drug candidates into development and thereby increase the value of their R&D discovery programmes. Over the past five years, Sygnature has established an enviable reputation and excellent track record of success with an international client base.
For more information on Sygnature CSL visit www.sygnaturechem.com.
About Heptares Therapeutics Ltd.
Heptares is a drug discovery company focused on identifying novel drug candidates targeting validated G-protein-coupled receptors (GPCRs) in several disease areas. Based on its unique StaR™ technology platform, Heptares has built an integrated drug discovery capability and aims to progress promising candidates internally and through strategic alliances.
GPCRs are the single most important family of drug targets in the human body, but because of their inherent instability they are refractory to structural studies and biochemical screening. StaR technology enables the engineering of stabilised GPCRs, making them amenable to these vital drug discovery approaches. There are many clinically relevant GPCR targets across a wide range of therapeutic areas where discovery is advancing slowly and for which structural information, novel screening approaches and potential antibody therapeutics would greatly enhance progress.
Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares’ founding scientists at the MRC Laboratory of Molecular Biology (Cambridge, UK) and the National Institute for Medical Research (London, UK).
2009 Sygnature Chemical Services Ltd. All rights reserved.
Sygnature Chemical Services Ltd. is a company incorporated in England, with company number 05210563, whose registered office and principal place of business is at BioCity, Pennyfoot Street, Nottingham, NG1 1GF, United Kingdom.